ReviewNature reviews. Rheumatology2017
Pathogenesis of ankylosing spondylitis - recent advances and future directions.
Review in Nature reviews. Rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Multi-layered functional genomics prioritizes candidate effectors and regulatory mechanisms of ankylosing spondylitis.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials.BMC medicine · 2024Pooled it
- Development of ankylosing spondylitis in patients with ulcerative colitis: A systematic meta-analysis.PloS one · 2023Pooled it
- Investigating the causal relationship between ankylosing spondylitis and osteoporosis in the European population: a bidirectional Mendelian randomization study.Frontiers in immunology · 2023Pooled it
- Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2023Pooled it
- Imbalance of Peripheral Lymphocyte Subsets in Patients With Ankylosing Spondylitis: A Meta-Analysis.Frontiers in immunology · 2021Pooled it
- Protective effect of anthrax toxin receptor 2 polymorphism rs4333130 against the risk of ankylosing spondylitis.Medicine · 2020Pooled it
- Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis.BMC pharmacology & toxicology · 2025Trial
- Trial
- Exploring inflammatory signatures in arthritic joint biopsies with Spatial Transcriptomics.Scientific reports · 2019Trial
- Molecular mechanisms linking cadmium chloride exposure to ankylosing spondylitis: an integrative network-based study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Recent updates in human leukocyte antigen B27-associated uveitis.Indian journal of ophthalmology · 2026Review
- Clinical applications and methodology updates in HLA typing.BMC immunology · 2026Review
- Thyroid hormone changes after tumor necrosis factor inhibitor therapy in euthyroid patients with rheumatic diseases.BMC pharmacology & toxicology · 2026Article
- Global research status and trends in the treatment of ankylosing spondylitis from 2005 to 2024: a bibliometric analysis.Clinical rheumatology · 2026Review
- Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.Biologics : targets & therapy · 2026Review
- The causal relationship between cathepsins and ankylosing spondylitis: a two-sample Mendelian randomization study.Therapeutic advances in musculoskeletal disease · 2026Article
- Restoring immune homeostasis in the spinal microenvironment: targeting mechano-inflammation and immunometabolic reprogramming.Frontiers in immunology · 2026Review
- Erosive costovertebral joint arthritis as a novel feature of ankylosing spondylitis.Quantitative imaging in medicine and surgery · 2025Article
- Elevated serum interleukin-41 levels as a potential biomarker in ankylosing spondylitis.Future science OA · 2025Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 5 years, advances in high-throughput techniques and studies involving large cohorts of patients have led to considerable advances in the identification of novel genetic associations and immune pathways involved in ankylosing spondylitis (AS). These discoveries include genes encoding cytokine receptors, transcription factors, signalling molecules and transport proteins. Although progress has been made in understanding the functions and potential pathogenic roles of some of these molecules, much work remains to be done to comprehend their complex interactions and therapeutic potential in AS. In this Review, we outline the current knowledge of AS pathogenesis, including genetic risk associations, HLA-B27-mediated pathology, perturbations in antigen-presentation pathways and the contribution of the type 3 immune response.
Indexed as
Identifiers
28446810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.